Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukaemia in first complete remission

• Published in: Bone marrow transplantation (Basingstoke) Vol. 8; no. 1; pp. 19 - 26
• Main Authors: GILMORE, M. J. M. L, HAMON, M. D, SECKER-WALKER, L. M, SKEGGS, D, COLLIS, C. H, PRENTICE, H. G, KATZ, F, SLAPER-CORTENBACH, I. C. M, HUNTER, A. E, GANDHI, L, BRENNER, M. K, HOFFBRAND, A. V, MEHTA, A. B
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing Group 01.07.1991
• Subjects: Adolescent; Adult; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Antibodies, Monoclonal - immunology; Antigens, CD - immunology; Antigens, CD19; Antigens, CD7; Antigens, Differentiation - immunology; Antigens, Differentiation, B-Lymphocyte - immunology; Antigens, Differentiation, T-Lymphocyte - immunology; Antigens, Neoplasm - immunology; Biological and medical sciences; Bone Marrow Transplantation - adverse effects; Bone marrow, stem cells transplantation. Graft versus host reaction; Child; Female; Humans; Immunophenotyping; Male; Medical sciences; Middle Aged; Neprilysin; Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology; Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology; Precursor Cell Lymphoblastic Leukemia-Lymphoma - surgery; Recurrence; Retrospective Studies; Risk Factors; Transfusions. Complications. Transfusion reactions. Cell and gene therapy; Transplantation, Autologous; Human; Animal origin; Complement; Malignant hemopathy; Monoclonal antibody; Result; Autograft; Depletion; Treatment; Bone marrow; Graft; Acute lymphocytic leukemia; Tumor cell
• ISSN: 0268-3369; 1476-5365

Patients in first remission of acute lymphoblastic leukaemia (ALL) considered to be at high risk of relapse were offered autologous bone marrow transplantation (ABMT) using purged marrow as a therapeutic alternative to cranial irradiation and maintenance chemotherapy. Twenty-seven bone marrows taken in remission, were purged using monoclonal antibodies (anti CD7 for T lineage and anti CD10 and/or anti CD19 for B lineage leukaemias) plus rabbit complement. Retrospective analysis of 19 purged marrows by immunophenotyping or immunoglobulin gene rearrangement studies demonstrated no evidence of disease. Engraftment was seen in 26 of the patients. No correlation was found between the numbers of infused nucleated cells or colony forming units-granulocyte-macrophage (CFU-GM) and subsequent engraftment kinetics. The actuarial disease-free survival (DFS) is 32% at 7 years (median follow-up 3.4 years). There were two transplant related deaths (actuarial risk 8%); the main cause of treatment failure has been disease recurrence with an overall actuarial risk of 67%; 76% for T-ALL (five of nine), 62% for common ALL (five of 10), two of five pre B and none of three patients with B-ALL. In these 27 high risk patients in vitro purging of remission marrow as part of ABMT appears not to improve patient outcome, although confirmation of this would require a randomized trial.